ClinicalTrials.gg

Program

Triamcinolone Acetonide

Also written as “triamcinolone acetonide”, “SC CLS-TA” and “suprachoroidal CLS-TA”.

Its studies are mostly in Macular Edema · Uveitis · Diabetes Mellitus · Keloid · Pain, led by 12 companies.

Furthest: phase 3, since Oct 28, 201520 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Clearside Biomedical70 open or runningphase 3since Oct 28, 2015Feb 5, 2013none ahead
Pacira BioSciences21 open or runningphase 3since Feb 13, 2024Feb 13, 2024Dec 2026phase 3 · NCT06269705
Sanofi20 open or runningphase 3since Jun 26, 2006Jun 26, 2006none ahead
Alcon10 open or runningphase 3since Sep 19, 2007Sep 19, 2007none ahead
Biosplice Therapeutics10 open or runningphase 1since Oct 6, 2020Oct 6, 2020none ahead
GlaxoSmithKline10 open or runningphase 1since Oct 31, 2013Oct 31, 2013none ahead
Harrow11 open or runningphase 3since Sep 14, 2026Sep 14, 2026Dec 2026phase 3 · NCT07832552
Merck10 open or runningphase 2since Jun 4, 2008Jun 4, 2008none ahead
Novartis10 open or runningphase 3since Oct 19, 2005Oct 19, 2005none ahead
Oxular10 open or runningphase 2since Aug 20, 2022Aug 20, 2022none ahead
PT. Prodia Stem Cell Indonesia10 open or runningphase 2since Mar 26, 2020Mar 26, 2020none ahead
SurModics10 open or runningphase 1since Jun 4, 2009Jun 4, 2009none ahead

Also a collaborator on its studies: QLT.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 6 studies since Oct 19, 2005.

  1. Oct 31, 2013GlaxoSmithKline’s first study: phase 1 study in FibrosisNew to GlaxoSmithKlineGlaxoSmithKline · NCT01978301 · 9 enrolled · United Kingdom
  2. Oct 28, 2015Phase 3 study in UveitisClearside Biomedical · NCT02595398 · 160 enrolled · United States, India, Israel
  3. Oct 25, 2016Phase 2 study in Diabetes MellitusClearside Biomedical · NCT02949024 · 20 enrolled · United States
  4. Nov 30, 2016Phase 3 study in Macular EdemaClearside Biomedical · NCT02980874 · 460 enrolled · United States, Australia, Austria and more
  5. Mar 27, 2017Phase 3 study in UveitisClearside Biomedical · NCT03097315 · 38 enrolled · United States
  6. Apr 20, 2017Phase 2 study in Diabetes MellitusClearside Biomedical · NCT03126786 · 71 enrolled · United States
  7. Jun 28, 2017Phase 3 study in Macular EdemaClearside Biomedical · NCT03203447 · 325 enrolled · United States, Australia, Hungary and more
  8. Oct 18, 2017Phase 3 study in Rhinitis, Allergic, PerennialSanofi · NCT03317015 · 260 enrolled
  9. Mar 26, 2020PT. Prodia Stem Cell Indonesia’s first study: phase 2 study in KeloidNew to PT. Prodia Stem Cell IndonesiaPT. Prodia Stem Cell Indonesia · NCT04326959 · 24 enrolled
  10. Oct 6, 2020Biosplice Therapeutics’ first study: phase 1 study in Drug-Drug InteractionNew to Biosplice TherapeuticsBiosplice Therapeutics · NCT04598542 · 40 enrolled · United States
  11. Aug 20, 2022Oxular’s first study: phase 2 study in Diabetic Macular EdemaNew to OxularOxular · NCT05512962 · 25 enrolled · United States
  12. Feb 13, 2024Pacira BioSciences’ first study: phase 3 study in Glenohumeral OsteoarthritisNew to Pacira BioSciencesPacira BioSciences · NCT06269705 · 150 enrolled · United States
  13. May 7, 2025Phase 2 study in Osteoarthritis, HipPacira BioSciences · NCT06977568 · 1 enrolled · United States
  14. Sep 14, 2026Harrow’s first study: phase 3 study in Postoperative Ocular InflammationNew to HarrowHarrow · NCT07832552 · 250 planned · United States

Ahead

  1. Dec 2026Primary completion: phase 3 study in Postoperative Ocular InflammationHarrow · NCT07832552
  2. Dec 2026Primary completion: phase 3 study in Glenohumeral OsteoarthritisPacira BioSciences · NCT06269705

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor agonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
DexamethasoneruleAbbViephase 4174
BudesonideruleAstraZenecaphase 4167
fluticasone furoateruleGlaxoSmithKlinephase 497
PrednisoneruleJohnson & Johnsonphase 465
BeclomethasoneruleChiesi Farmaceuticiphase 446
PrednisoloneruleSanofiphase 434
betamethasone dipropionateruleLEO Pharmaphase 427
MethylprednisolonerulePfizerphase 423
dexamethasone phosphateruleeyegate-pharmaceuticals-incphase 421
BetamethasoneruleLEO Pharmaphase 49
Triamcinoloneruleresearch-insight-llcphase 45
relacorilantruleCorcept Therapeuticsphase 322

Studies

All 20 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07832552Postoperative Ocular Inflammation · United States3By invitationHarrowDec 2026250
NCT06977568Osteoarthritis, Hip · United States2TerminatedPacira BioSciencesOct 16, 20251
NCT06269705Glenohumeral Osteoarthritis · United States3Active, not recruitingPacira BioSciencesDec 2026150
NCT05512962Diabetic Macular Edema · United States2CompletedOxularNov 30, 202325
NCT04598542Drug-Drug Interaction · United States1CompletedBiosplice TherapeuticsDec 22, 202040
NCT04326959Keloid2UNKNOWNPT. Prodia Stem Cell IndonesiaSep 8, 202024
NCT03317015Rhinitis, Allergic, Perennial3CompletedSanofiJul 10, 2017260
NCT03203447Macular Edema · United States, Australia, Hungary and more3TerminatedClearside BiomedicalDec 18, 2018325
NCT03126786Diabetes Mellitus · United States2CompletedClearside BiomedicalApr 17, 201871
NCT03097315Uveitis · United States3CompletedClearside BiomedicalJan 24, 201838
NCT02980874Macular Edema · United States, Australia, Austria and more3TerminatedClearside BiomedicalDec 10, 2018460
NCT02949024Diabetes Mellitus · United States2CompletedClearside BiomedicalOct 17, 201720
NCT02595398Uveitis · United States, India, Israel3CompletedClearside BiomedicalJan 18, 2018160
NCT01978301Fibrosis · United Kingdom1TerminatedGlaxoSmithKlineFeb 5, 20159
NCT01789320Uveitis · United States2CompletedClearside BiomedicalMar 201511
NCT00915837Diabetic Macular Edema · United States1CompletedSurModicsApr 200931
NCT00692614Macular Edema2TerminatedMerckNov 20082
NCT00532415Vitrectomy3CompletedAlconSep 200760
NCT00344942Rhinitis · France3TerminatedSanofiApr 200777
NCT00242580Macular Degeneration · United States3CompletedNovartisJan 2008111

How it is read

Names in the registry

  • “triamcinolone acetonide”, 4 entries
  • “Triamcinolone Acetonide”, 2 entries
  • “SC CLS-TA”, 2 entries
  • “suprachoroidal CLS-TA”, 2 entries
  • “Triamcinolone acetonide”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.